Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine
β Scribed by A Lepetic; C Biscayart; M Seigelchifer; R Arduino; D Stamboulian
- Book ID
- 117431655
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 91 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0264-410X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A combined hepatitis A and B vaccine is available since 1996. Two separate openβlabel primary studies evaluated the immunogenicity and safety of this hepatitis A and B vaccine (720βEI.U of HAV and 20βΒ΅g of HBsAg) in 306 healthy subjects aged 17β43 years who received three doses of the v
A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasmaderived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBs